Specifications and Tests

ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances And New Drug Products: Chemical Substances
ICH Q6A: Specifications: Decision Tree
ICH Q6B: Specifications: Test procedures and Acceptance criteria for Biotechnological / Biological products
ICH Q3A(R2): Impurities in new Drug substances
ICH Q3B(R2): Impurities in new Drug products
ICH Q3C(R8) Impurities: Guideline for Residual Solvents
ICH Q3D(R2): Guideline for Elemental Impurities
ICH M7(R2): Assessment and control of DNA reactive (Mutagenic) impurities in Pharmaceuticals to limit potential Carcinogenic risk
ICH Addendum to M7(R2): Application of the principles of the ICH M7 Guideline to calculation of compound-specific Acceptable Intakes
ICH M7(R2): 2nd Addendum Step 4 document.
ICH M7(R2) Q&As: Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk; Questions and Answers
VICH: GL39 Test procedures and acceptance criteria for new veterinary drug substances and new medicinal products: chemical substances – Scientific guideline (VICH: GL39)
EMA (European Medicines Agency): Specifications and control tests on the finished product – Scientific guideline
EMA (European Medicines Agency): Setting specifications for related impurities in antibiotics – Scientific guideline
USP General chapters: General Tests & Assays – General requirements for tests and assays (Access from USP)
- Chapter 1: Injections and Implanted Drug Products (Parenterals)—Product Quality Tests
- Chapter 2: Oral Drug Products—Product Quality Tests
- Chapter 3: Topical and Transdermal Drug Products—Product Quality Tests
- Chapter 4: Mucosal Drug Products—Product Quality Tests
- Chapter 5: Inhalation and Nasal Drug Products—General Information and Product Quality Tests
USP<1111> Microbiological Attributes of Nonsterile Pharmaceutical products & USP <1111>: Microbiological examination of Nonsterile products: Acceptance criteria for Pharmaceutical preparations Substances for Pharmaceutical use (Access from USP)
USP<1115> Bioburden Control Of Nonsterile Drug Substances And Products (Access from USP)
USFDA: Microbiological Quality Considerations in Non-Sterile Drug Manufacturing
USFDA: FDA advises drug manufacturers that Burkholderia cepacia complex (BCC) poses a contamination risk in non-sterile, water-based drug products
European Pharmacopeia (Access from EP or Ph.Eur):
- Substances for Pharmaceutical Use (2034);
- 10. Control of impurities in substances for Pharmaceutical use (51000)
- 4. Residual Solvents
USFDA : Policy on testing ethanol isopropyl alcohol for methanol
USFDA: Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol

Qvents

Discussion forum for Pharma Quality events, Regulatory Actions

Specifications and Tests

Qvents Team

Search Posts

Latest Posts

Imprimis Recall Unapproved Ophthalmic Injections for Glass Particulates in US

Laboratory Incidents and Validation Failures Lead to USFDA Warning Letter for Cdymax

Qvents Apps and Tools For QMS and GMP Processes

Hetero USFDA Form 483: Unregistered Testing Lab, Undocumented Warehouse

Zydus Recalls Antipsychotic Drug for Nitroso Desmethylchlorpromazine NDSRI